[1]
|
Barušić, A.K. (2022) The Emerging Role of Olanzapine in Paediatric CINV Control: A Review. Medicine, 101, e32116. https://doi.org/10.1097/MD.0000000000032116
|
[2]
|
Hesketh, P.J. (2008) Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine, 358, 2482-2494. https://doi.org/10.1056/NEJMra0706547
|
[3]
|
Shankar, A., Roy, S., Malik, A., Julka, P.K. and Rath, G.K. (2015) Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients. Asian Pacific Journal of Cancer Preven-tion, 16, 6207-6213.
https://doi.org/10.7314/APJCP.2015.16.15.6207
|
[4]
|
Aapro, M. (2018) CINV: Still Troubling Patients after All These Years. Support Care Cancer, 26, 5-9.
https://doi.org/10.1007/s00520-018-4131-3
|
[5]
|
Andrews, P.L. and Sanger, G.J. (2002) Abdominal Vagal Affer-ent Neurones: An Important Target for the Treatment of Gastrointestinal Dysfunction. Current Opinion in Pharmacology, 2, 650-656.
https://doi.org/10.1016/S1471-4892(02)00227-8
|
[6]
|
Navari, R.M. and Aapro, M. (2016) Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine, 374, 1356-1367. https://doi.org/10.1056/NEJMra1515442
|
[7]
|
de Boer-Dennert, M., de Wit, R., Schmitz, P.I., et al. (1997) Patient Perceptions of the Side-Effects of Chemotherapy: The Influence of 5HT3 Antagonists. British Journal of Cancer, 76, 1055-1061. https://doi.org/10.1038/bjc.1997.507
|
[8]
|
Stern, R.M., Koch, K.L. and Andrews, P.L.R. (2011) Nau-sea: Mechanisms and Management. Oxford, New York.
|
[9]
|
Navari, R.M. (2009) Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Recent Developments. Drugs, 69, 515-533. https://doi.org/10.2165/00003495-200969050-00002
|
[10]
|
姜文奇, 巴一, 冯继锋, 等. 肿瘤药物治疗相关恶心呕吐防治中国专家共识(2019年版) [J]. 中国医学前沿杂志(电子版), 2019, 11(11): 16-26.
|
[11]
|
Bymaster, F.P., Falcone, J.F., Bauzon, D., Kennedy, J.S., Schenck, K., DeLapp, N.W. and Cohen, M.L. (2001) Potent Antagonism of 5-HT3 and 5-HT6 Receptors by Olanzapine. European Journal of Pharmacology, 430, 341-349.
https://doi.org/10.1016/S0014-2999(01)01399-1
|
[12]
|
Srivastava, M., Brito-Dellan, N., Davis, M.P., Leach, M. and Lagman, R. (2003) Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer. Journal of Pain and Symptom Management, 25, 578-582.
https://doi.org/10.1016/S0885-3924(03)00143-X
|
[13]
|
Passik, S.D., Navari, R.M., Jung, S.H., Nagy, C., Vinson, J., Kirsh, K.L. and Loehrer, P. (2004) A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study. Cancer Investigation, 22, 383-388. https://doi.org/10.1081/CNV-200029066
|
[14]
|
Navari, R.M., Einhorn, L.H., Passik, S.D., Loehrer Sr., P.J., John-son, C., Mayer, M.L., McClean, J., Vinson, J. and Pletcher, W. (2005) A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. Supportive Care in Cancer, 13, 529-534.
https://doi.org/10.1007/s00520-004-0755-6
|
[15]
|
Vimolchalao, V., Sakdejayont, S., Wongchanapai, P., Sukprakun, S., Angspatt, P., Thawinwisan, W., Chenaksara, P., Sriuranpong, V., Vinayanuwatikun, C., Parinyanitikun, N., Poo-vorawan, N. and Tanasanvimon, S. (2020) The Efficacy and Safety of the Addition of Olanzapine to Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy. International Journal of Clinical Oncology, 25, 396-402. https://doi.org/10.1007/s10147-019-01570-3
|
[16]
|
Chiou, T.J., Tzeng, W.F., Wang, W.S., Yen, C.C., Fan, F.S., Liu, J.H. and Chen, P.M. (2000) Comparison of the Efficacy and Safety of Oral Granisetron plus Dexamethasone with Intra-venous Ondansetron plus Dexamethasone to Control Nausea and Vomiting Induced by Moderate/Severe Emetogenic Chemotherapy. Chinese Medical Journal, 63, 729-736.
|
[17]
|
Patil, V., Prasada, H., Prasad, K. and Shenoy, U.V. (2015) Comparison of Antiemetic Efficacy and Safety of Palonosetron vs Ondansetron in the Prevention of Chemothera-py-Induced Nausea and Vomiting in Children. The Journal of Community and Supportive Oncology, 13, 209-213. https://doi.org/10.12788/jcso.0139
|
[18]
|
Candelario, N. and Lu, M.L. (2016) Fosaprepitant Dimeglumine for the Management of Chemotherapy-Induced Nausea and Vomiting: Patient Selection and Perspectives. Cancer Management and Research, 8, 77-82.
https://doi.org/10.2147/CMAR.S93620
|
[19]
|
Grunberg, S., Chua, D., Maru, A., Dinis, J., DeVandry, S., Boice, J.A., Hardwick, J.S., Beckford, E., Taylor, A., Carides, A., Roila, F. and Herrstedt, J. (2011) Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE. Journal of Clinical Oncology, 29, 1495-1501. https://doi.org/10.1200/JCO.2010.31.7859
|
[20]
|
Mantovani, G., Maccio, A., Esu, S. and Lai, P. (1996) Evidence That Cisplatin Induces Serotoninrelease from Human Peripheral Blood Mononuclear Cells and That Methylprednisolone Inhibits This Effect. European Journal of Cancer, 32, 1983-1985. https://doi.org/10.1016/0959-8049(96)00204-3
|
[21]
|
Ho, C.M., Ho, S.T., Wang, J.J., et al. (2004) Dexamethasone Has a Central Antiemetic Mechanism in Decerebrated Cats. Anesthesia & Analgesia, 99, 734-739. https://doi.org/10.1213/01.ANE.0000130003.68288.C7
|
[22]
|
Ibrahim, E.M., Al-Idrissi, H.Y., Ibrahim, A., et al. (1986) Antiemetic Efficacy of High-Dose Dexamethasone: Randomized, Double-Blind, Crossover Study with High-Dose Metoclopramide in Patients Receiving Cancer Chemotherapy. European Journal of Cancer and Clinical On-cology, 22, 283-288. https://doi.org/10.1016/0277-5379(86)90392-5
|
[23]
|
Ioannidis, J.P., Hesketh, P.J. and Lau, J. (2000) Contribution of Dexamethasone to Control Ofchemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence. Journal of Clinical Oncology, 18, 3409-3422.
https://doi.org/10.1200/JCO.2000.18.19.3409
|
[24]
|
Jordan, K., Kasper, C. and Schmoll, H.J. (2005) Chemothera-py-Induced Nausea and Vomiting: Current and New Standards in the Antiemetic Prophylaxis and Treatment. European Journal of Cancer, 41, 199-205.
https://doi.org/10.1016/j.ejca.2004.09.026
|
[25]
|
Zaglama, N.E., Rosenblum, S.L., Sartiano, G.P., et al. (1986) Sin-gle, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy. Oncology, 43, 27-32. https://doi.org/10.1159/000226099
|